Cancer Research
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Excerpt from the Press Release:…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the Best Places to Work for the second year in a row. Surface was among…
Read More
XL114 is a CARD11-BCL10-MALT1 pathway inhibitor with demonstrated activity in lymphoma models that are resistant to Bruton’s tyrosine kinase inhibitors – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Apr. 14, 2022– Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114, a novel anti-cancer compound that inhibits the…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, April 13, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy…
Read More
– Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors – Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a novel mechanism – Loading CAR T cells with pelareorep led to dramatic improvements in their persistence and anti-cancer activity as…
Read More
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer Excerpt from the Press Release: CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies…
Read More
— Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life — — Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients – Excerpt from the Press Release: SAN CARLOS, Calif., April 13, 2022 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of preclinical data and initial…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association…
Read More
– Promising efficacy seen including in patients with PD-L1 low tumors – Favorable safety profile with minimal additive safety burden in combination – Updated results of the ongoing study presented in oral presentation at American Association for Cancer Research (AACR) Annual Meeting Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., April 12, 2022 /PRNewswire/ — Trishula Therapeutics, Inc., a…
Read More
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
New Research from Trinity College Dublin Indicates Broader Therapeutic Potential for ART27.13 Excerpt from the Press Release: SOLANA BEACH, Calif., April 13, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that ART27.13, a peripherally selective…
Read More